WO2002034753A3 - Inhibiteurs de metalloproteinase spiro-pyrimidine-2,4,6-trione - Google Patents

Inhibiteurs de metalloproteinase spiro-pyrimidine-2,4,6-trione Download PDF

Info

Publication number
WO2002034753A3
WO2002034753A3 PCT/IB2001/001986 IB0101986W WO0234753A3 WO 2002034753 A3 WO2002034753 A3 WO 2002034753A3 IB 0101986 W IB0101986 W IB 0101986W WO 0234753 A3 WO0234753 A3 WO 0234753A3
Authority
WO
WIPO (PCT)
Prior art keywords
spiro
pyrimidine
metalloproteinase inhibitors
trione metalloproteinase
trione
Prior art date
Application number
PCT/IB2001/001986
Other languages
English (en)
Other versions
WO2002034753A2 (fr
Inventor
Brian Scott Bronk
Mark Carl Noe
Martin James Wythes
Original Assignee
Pfizer Prod Inc
Brian Scott Bronk
Mark Carl Noe
Martin James Wythes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2002537743A priority Critical patent/JP2004518635A/ja
Priority to AU2002210813A priority patent/AU2002210813A1/en
Application filed by Pfizer Prod Inc, Brian Scott Bronk, Mark Carl Noe, Martin James Wythes filed Critical Pfizer Prod Inc
Priority to CA002425283A priority patent/CA2425283A1/fr
Priority to PL01366201A priority patent/PL366201A1/xx
Priority to APAP/P/2001/002318A priority patent/AP2001002318A0/en
Priority to IL15494801A priority patent/IL154948A0/xx
Priority to SK497-2003A priority patent/SK4972003A3/sk
Priority to KR10-2003-7005753A priority patent/KR20040004412A/ko
Priority to HU0301577A priority patent/HUP0301577A3/hu
Priority to EA200300306A priority patent/EA005762B1/ru
Priority to EEP200300196A priority patent/EE200300196A/xx
Priority to EP01978721A priority patent/EP1332146A2/fr
Priority to MXPA03003735A priority patent/MXPA03003735A/es
Priority to BR0114913-0A priority patent/BR0114913A/pt
Publication of WO2002034753A2 publication Critical patent/WO2002034753A2/fr
Publication of WO2002034753A3 publication Critical patent/WO2002034753A3/fr
Priority to BG107653A priority patent/BG107653A/bg
Priority to IS6762A priority patent/IS6762A/is
Priority to NO20031853A priority patent/NO20031853L/no
Priority to HR20030332A priority patent/HRP20030332A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)

Abstract

La présente invention concerne des inhibiteurs de métalloprotéinase 5-spiro-pyrimidine-2,4,6-trione selon la formule (I), où 'A' est un noyau hétérocyclique à 5-7 éléments, tel qu'il est défini dans la spécification, ainsi que des compositions et des procédés pharmaceutiques pour traiter des inflammations, le cancer et d'autres maladies.
PCT/IB2001/001986 2000-10-26 2001-10-23 Inhibiteurs de metalloproteinase spiro-pyrimidine-2,4,6-trione WO2002034753A2 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
EEP200300196A EE200300196A (et) 2000-10-26 2001-10-23 Spiropürimidiin-2,4,6-trioonmetalloproteinaasi inhibiitorid
EA200300306A EA005762B1 (ru) 2000-10-26 2001-10-23 Спиро-пиримидин-2,4,6-трионовые ингибиторы металлопротеиназы
EP01978721A EP1332146A2 (fr) 2000-10-26 2001-10-23 Inhibiteurs de metalloproteinase spiro-pyrimidine-2,4,6-trione
AU2002210813A AU2002210813A1 (en) 2000-10-26 2001-10-23 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
APAP/P/2001/002318A AP2001002318A0 (en) 2000-10-26 2001-10-23 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
IL15494801A IL154948A0 (en) 2000-10-26 2001-10-23 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
SK497-2003A SK4972003A3 (en) 2000-10-26 2001-10-23 5-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
KR10-2003-7005753A KR20040004412A (ko) 2000-10-26 2001-10-23 스피로-피리미딘-2,4,6-트리온 메탈로프로테이나제 억제제
HU0301577A HUP0301577A3 (en) 2000-10-26 2001-10-23 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors, pharmaceutical compositions containing them and their use
JP2002537743A JP2004518635A (ja) 2000-10-26 2001-10-23 スピロ−ピリミジン−２，４，６−トリオンメタロプロテイナーゼ阻害剤
PL01366201A PL366201A1 (en) 2000-10-26 2001-10-23 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
CA002425283A CA2425283A1 (fr) 2000-10-26 2001-10-23 Inhibiteurs de metalloproteinase spiro-pyrimidine-2,4,6-trione
MXPA03003735A MXPA03003735A (es) 2000-10-26 2001-10-23 Inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas.
BR0114913-0A BR0114913A (pt) 2000-10-26 2001-10-23 Inibidores de metaloproteinase de espiro-pirimidina-2,4,6-triona
BG107653A BG107653A (bg) 2000-10-26 2003-03-20 Спиро-пиримидин - 2,4,6-трионови инхибитори на металопротеиназa
IS6762A IS6762A (is) 2000-10-26 2003-03-27 Spíró-pýrimídín-2,4,6-tríón málmpróteinasa hindrar
NO20031853A NO20031853L (no) 2000-10-26 2003-04-24 Spiro-pyrimidin-2,4,6-trion metalloproteinaseinhibitorer
HR20030332A HRP20030332A2 (en) 2000-10-26 2003-04-28 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24338900P 2000-10-26 2000-10-26
US60/243,389 2000-10-26

Publications (2)

Publication Number Publication Date
WO2002034753A2 WO2002034753A2 (fr) 2002-05-02
WO2002034753A3 true WO2002034753A3 (fr) 2002-08-15

Family

ID=22918584

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/001986 WO2002034753A2 (fr) 2000-10-26 2001-10-23 Inhibiteurs de metalloproteinase spiro-pyrimidine-2,4,6-trione

Country Status (32)

Country Link
EP (1) EP1332146A2 (fr)
JP (1) JP2004518635A (fr)
KR (1) KR20040004412A (fr)
CN (1) CN1501937A (fr)
AP (1) AP2001002318A0 (fr)
AR (1) AR035069A1 (fr)
AU (1) AU2002210813A1 (fr)
BG (1) BG107653A (fr)
BR (1) BR0114913A (fr)
CA (1) CA2425283A1 (fr)
CZ (1) CZ20031083A3 (fr)
EA (1) EA005762B1 (fr)
EC (1) ECSP034567A (fr)
EE (1) EE200300196A (fr)
GT (1) GT200100213A (fr)
HN (1) HN2001000244A (fr)
HR (1) HRP20030332A2 (fr)
HU (1) HUP0301577A3 (fr)
IL (1) IL154948A0 (fr)
IS (1) IS6762A (fr)
MA (1) MA26957A1 (fr)
MX (1) MXPA03003735A (fr)
NO (1) NO20031853L (fr)
OA (1) OA12529A (fr)
PA (1) PA8531401A1 (fr)
PE (1) PE20020589A1 (fr)
PL (1) PL366201A1 (fr)
SK (1) SK4972003A3 (fr)
SV (1) SV2003000705A (fr)
TN (1) TNSN01149A1 (fr)
WO (1) WO2002034753A2 (fr)
ZA (1) ZA200302190B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2002000328A (es) 2001-02-14 2003-08-30 Warner Lambert Co Pirimidinas inhibidoras de metaloproteinasas de matriz
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
EP1368327B1 (fr) 2001-02-14 2004-10-20 Warner-Lambert Company LLC Benzo-thiadiazines inhibitrices des metalloproteinases matricielles
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
JP4164028B2 (ja) 2001-10-12 2008-10-08 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アルキンマトリックスメタロプロテイナーゼ阻害剤
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
AU2003228701A1 (en) * 2002-04-25 2003-11-10 Bristol-Myers Squibb Company Spirobarbituric acid derivatives useful as inhibitors of matrix metalloproteases
AU2003216660A1 (en) * 2002-04-26 2003-11-10 Pfizer Products Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
BR0309281A (pt) * 2002-04-26 2005-02-22 Pfizer Prod Inc Triaril-oxi-espiro-pirimidino-2,4,6-trionas inibidoras de metaloproteinases
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
AU2003249477A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
ES2283851T3 (es) 2002-08-13 2007-11-01 Warner-Lambert Company Llc Derivados de pirimidin-2,4-diona como inhibidores de las metaloproteinasas de matriz.
EP1537090A1 (fr) 2002-08-13 2005-06-08 Warner-Lambert Company Llc Derives de chromone inhibiteurs de metalloproteinase de matrice
WO2004014909A1 (fr) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Derives fusionnes de la tetrahydropyridine inhibiteurs de la metalloprotease matricielle
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
AU2003249531A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
AU2003249540A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
AU2003250470A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
JP2006501215A (ja) 2002-08-13 2006-01-12 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体
US7208490B2 (en) 2002-10-07 2007-04-24 Pharmacia & Upjohn Company Llc Tricyclic tetrahydroquinoline antibacterial agents
GB0223249D0 (en) * 2002-10-08 2002-11-13 Amersham Plc Improved imaging agents
WO2004084903A1 (fr) * 2003-03-27 2004-10-07 F. Hoffmann-La Roche Ag Utilisation d'une trioxopyrimidine pour le traitement et la prevention de l'angiogenese pathologique oculaire
WO2004084902A1 (fr) * 2003-03-28 2004-10-07 F. Hoffmann-La Roche Ag Utilisation d'une trioxopyrimidine dans le traitement de lesions chroniques
FR2858232B1 (fr) * 2003-07-29 2006-03-03 Pierre Potier Utilisation d'un derive de biguanide pour proteger la peau des radiations uvb
RU2402329C2 (ru) * 2004-04-01 2010-10-27 Юниверсите Де-Льеж Применение триоксопиримидина для лечения и предупреждения воспалительных заболеваний бронхов
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
US8153166B2 (en) * 2006-06-08 2012-04-10 Chih-Hsiung Lin Composition for prophylaxis or treatment of urinary system infection and method thereof
CN102285934B (zh) * 2009-01-08 2013-08-14 四川大学 螺环二烯酮衍生物及其制备方法和用途
ES2663797T3 (es) * 2012-12-10 2018-04-17 Chugai Seiyaku Kabushiki Kaisha Derivados de hidantoína
KR101594506B1 (ko) * 2014-03-20 2016-02-17 한국화학연구원 골 관련 질환 치료용 조성물
RU2701168C2 (ru) 2014-06-09 2019-09-25 Чугаи Сейяку Кабусики Кайся Фармацевтическая композиция, содержащая производные гидантоина
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
CN110092790B (zh) * 2019-06-11 2020-07-24 东北农业大学 一种生物碱类化合物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714093A (en) * 1970-05-19 1973-01-30 American Home Prod Spiro [heterocycloalkyl-2'(1'h)-quinazoline]-4'(3'h)-ones
WO1998058925A1 (fr) * 1997-06-21 1998-12-30 Roche Diagnostics Gmbh Derives d'acide barbiturique dotes d'une activite antimetastatique et anitumorale
WO2000047565A1 (fr) * 1999-02-12 2000-08-17 F. Hoffmann-La Roche Ag Pyrimidine-2,4,6-triones utilisees comme inhibiteurs des metalloproteinases matricielles
WO2001012611A1 (fr) * 1999-08-12 2001-02-22 Pfizer Products Inc. Inhibiteurs de pyrimidine-2,4,6-trione metalloproteinase

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714093A (en) * 1970-05-19 1973-01-30 American Home Prod Spiro [heterocycloalkyl-2'(1'h)-quinazoline]-4'(3'h)-ones
WO1998058925A1 (fr) * 1997-06-21 1998-12-30 Roche Diagnostics Gmbh Derives d'acide barbiturique dotes d'une activite antimetastatique et anitumorale
WO2000047565A1 (fr) * 1999-02-12 2000-08-17 F. Hoffmann-La Roche Ag Pyrimidine-2,4,6-triones utilisees comme inhibiteurs des metalloproteinases matricielles
WO2001012611A1 (fr) * 1999-08-12 2001-02-22 Pfizer Products Inc. Inhibiteurs de pyrimidine-2,4,6-trione metalloproteinase

Also Published As

Publication number Publication date
EA200300306A1 (ru) 2003-08-28
HUP0301577A3 (en) 2006-02-28
HN2001000244A (es) 2003-11-07
CZ20031083A3 (cs) 2004-03-17
ECSP034567A (es) 2003-06-25
AR035069A1 (es) 2004-04-14
SK4972003A3 (en) 2004-05-04
WO2002034753A2 (fr) 2002-05-02
IL154948A0 (en) 2003-10-31
BR0114913A (pt) 2003-07-01
NO20031853L (no) 2003-06-23
PL366201A1 (en) 2005-01-24
PE20020589A1 (es) 2002-07-06
BG107653A (bg) 2003-12-31
PA8531401A1 (es) 2003-06-30
CA2425283A1 (fr) 2002-05-02
MXPA03003735A (es) 2003-07-28
KR20040004412A (ko) 2004-01-13
TNSN01149A1 (fr) 2005-11-10
HRP20030332A2 (en) 2003-06-30
OA12529A (en) 2006-06-02
EP1332146A2 (fr) 2003-08-06
HUP0301577A2 (hu) 2003-11-28
NO20031853D0 (no) 2003-04-24
AP2001002318A0 (en) 2001-12-31
JP2004518635A (ja) 2004-06-24
SV2003000705A (es) 2003-01-13
MA26957A1 (fr) 2004-12-20
EE200300196A (et) 2003-10-15
EA005762B1 (ru) 2005-06-30
AU2002210813A1 (en) 2002-05-06
ZA200302190B (en) 2004-04-28
IS6762A (is) 2003-03-27
CN1501937A (zh) 2004-06-02
GT200100213A (es) 2002-07-03

Similar Documents

Publication Publication Date Title
WO2002034753A3 (fr) Inhibiteurs de metalloproteinase spiro-pyrimidine-2,4,6-trione
WO2003091259A8 (fr) Inhibiteurs de la triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase
WO2002034726A3 (fr) Inhibiteurs de la pyrimidine-2,4,6-trione metalloproteinase
YU69902A (sh) Novi derivati piperazina
BG106406A (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
WO2000055124A3 (fr) Composes et compositions utilises comme inhibiteurs de protease
WO2001066564A3 (fr) Inhibiteurs de gamma-sécrétase
EP1248612A4 (fr) Nouveaux composes et compositions utilises comme inhibiteurs de protease
WO2002036562A3 (fr) 1-aryl- ou 1-alkylsulfonyl-heterocyclylbenzazoles en tant que ligands de 5-hydroxytryptamine-6
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
RS50140B (sr) Postupak za dobijanje perkihinina i njegova upotreba
AU2002258066A1 (en) Dermatological and cosmetic compositions
AP1564A (en) Piperazinyl sulfonic acid derivatives, their pharmaceutical compositions and methods of use.
WO2002051832A3 (fr) Composes heterocyclylalkylindole ou azaindole comme ligands 5-hydroxytryptamine-6
WO2002051983A3 (fr) Composes et compositions en tant qu'inhibiteurs de cathepsine
SE9802208D0 (sv) Novel compounds
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
WO2002028860A3 (fr) Composes tetracycliques amino-substitues utiles en tant qu'agents anti-inflammatoires et compositions pharmaceutiques les contenant
YU30603A (sh) Derivati premošćenog piperazina
WO2001081332A3 (fr) Composes de 2-fluorobenzenesulfonyle utilises pour le traitement d'inflammations
WO2002051848A3 (fr) Sulfamidothienopyrimidines
SE9802209D0 (sv) Novel compounds
ATE250610T1 (de) Kaliumkanal-blockierende mittel
WO2001085760A8 (fr) Inhibiteurs de la thrombine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: AP/P/2001/002318

Country of ref document: AP

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 154948

Country of ref document: IL

Ref document number: 524773

Country of ref document: NZ

Ref document number: 310/MUMNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003/02190

Country of ref document: ZA

Ref document number: 200302190

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 10765301

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2002210813

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 20030390

Country of ref document: UZ

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200300306

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2425283

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PV2003-1083

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 4972003

Country of ref document: SK

Ref document number: 1200300376

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 6921

Country of ref document: GE

Ref document number: 5119

Country of ref document: GE

Ref document number: 1-2003-500290

Country of ref document: PH

Ref document number: 018179231

Country of ref document: CN

Ref document number: P-314/03

Country of ref document: YU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/003735

Country of ref document: MX

Ref document number: 1020037005753

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: P20030332A

Country of ref document: HR

Ref document number: 2001978721

Country of ref document: EP

Ref document number: 2002537743

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2001978721

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020037005753

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2003-1083

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 1020037005753

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2001978721

Country of ref document: EP